




UNITED STATES PATENT AND TRADEMARK OFFICE




UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/501,127	09/10/2004	Petrus Theodorus Johannes Willemssen	I-2002.032 US	6068
<div>31846 7590 03/17/2008</div> <div>INTERVET INC. PATENT DEPARTMENT PO BOX 318 MILLSBORO, DE 19966-0318</div> <div>EXAMINER SCHWADRON, RONALD B</div> <div>ART UNIT PAPER NUMBER</div> <div>1644</div> <div>MAIL DATE DELIVERY MODE</div> <div>03/17/2008 PAPER</div>				

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.





UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10501127	9/10/04	WILLEMSSEN ET AL.	I-2002.032 US

INTERVET INC.
PATENT DEPARTMENT
PO BOX 318
MILLSBORO, DE 19966-0318

EXAMINER

Ron Schwadron, Ph.D.

ART UNIT	PAPER
1644	200803

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The Sequence listing in paper form and CRF lack mandatory section <150> disclosing the priority documents and section <110> should list the names of the inventors of the instant application.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

/Ron Schwadron, Ph.D./
Primary Examiner, Art Unit 1644



Notice to Comply	Application No 10/501127	Applicant(s) Willemssen et al.	
	Examiner Ron Schwadron, Ph.D.	Art Unit 1644	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- X 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

X 7. Other: SEE ENCLOSED COMMUNICATION

Applicant Must Provide:

X An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

X An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.

X A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



COUNT SHEET FOR SEQUENCE CASES

Serial No. 10/501127

AE _____

Date of Count _____

Mark only one space below

(CRFN) (CRF is unreadable; use CRF Diskette
Problem Report)

XXXX

(CRFD) (CRF does not comply; use Notice to
Comply)

(CRFR) (CRF required but none submitted;
use Notice to Comply)

(bona fide) (second or subsequent letter to applicant
reporting bona fide attempt to comply;
use Notice to Comply and send copy
of RSL)

(non bona fide) (second or subsequent letter to
applicant reporting non-bona fide
attempt to comply; use
Notice to Comply and send

of RSL)

Examiner's Name: Ron Schwadron, Ph.D.

GAU: 1644



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Willemsen et al.

Serial No.: 10/501,127

Filed: September 10, 2004

For: PARAMYCOBACTERIAL
DIAGNOSTICS AND VACCINES

Confirmation No.: 6068

Examiner: R. Schwadron

Group Art Unit: 1644

Attorney Docket No.: 2183-8276US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV962542496US

Date of Deposit with USPS: March 24, 2008

Person making Deposit: Drew Greenhalgh

COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Attached is a copy of the Notice Regarding Power of Attorney mailed September 24, 2007. On September 5, 2007, Applicants submitted a Power of Attorney and Statement under 37 CFR 3.73(b). A copy of the return postcard, the Power of Attorney, and the Statement under 37 CFR 3.73(b) previously submitted are enclosed. Also enclosed are copies of the Notice of Recordation of Assignment and Assignment.

Applicants request that the records of the Patent Office be updated. Applicants also request that the correspondence address be updated so that subsequent communication from the Patent Office is directed to the attorneys at Customer Number 24247.

Serial No. 10/501,127

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Allen C. Turner', with a long horizontal flourish extending to the right.

Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: March 24, 2008
ACT/bv


COPY



THE PATENT & TRADEMARK OFFICE MAILROOM DATE
STAMPED HEREON IS AN ACKNOWLEDGEMENT THAT ON THIS
DATE THE PATENT & TRADEMARK OFFICE RECEIVED:

Transmittal Form (1 page, in duplicate); Power of Attorney and
Correspondence Address Indication Form (1 page); Statement under 37
CFR 3.73(b) (1 page)

Invention: PARAMYCOBACTERIAL DIAGNOSTICS AND
VACCINES
Applicant(s): Willemsen et al
Filing Date: September 10, 2004
Serial No.: 10/501,127
Date Sent: September 5, 2007 via first class mail
Docket No.: 2183-8276US
ACT/alb



SEP 13 2007

TRASK BRITT, P.C.